Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an Antimetabolite presented as an oral formulation for oral use. It acts as an immunosuppressant that helps prevent organ rejection in patients who have undergone renal transplantation, reducing the risk of graft failure.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for transplant programmes and adhering to EU Good Manufacturing Practice standards through a robust distribution network.

Myfortic is used in transplant medicine to suppress the immune response that can lead to graft rejection.

- Renal transplantation: helps prevent organ rejection and supports graft survival. - Heart transplantation: reduces the incidence of acute rejection episodes. - Liver transplantation: contributes to long‑term graft function by inhibiting lymphocyte proliferation.

Myfortic may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea. - Headache: mild to moderate intensity. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Hematologic changes: leukopenia or anemia. - Elevated liver enzymes: mild transaminase elevations.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal demyelinating disease. - Malignancy: increased risk of post‑transplant lymphoproliferative disorders.

When prescribing Myfortic, clinicians should consider several safety measures and monitoring requirements.

- Monitor blood counts: regular complete blood count to detect leukopenia or anemia. - Assess renal function: evaluate serum creatinine and eGFR periodically. - Check for infections: be vigilant for opportunistic infections and advise prophylaxis when appropriate. - Avoid use in patients with known hypersensitivity to mycophenolic acid. - Pregnancy and lactation: discuss potential risks and consider alternative therapy. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Myfortic can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection; avoid administration. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce mycophenolic acid exposure.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: can decrease absorption; separate dosing by at least 2 hours. - Azathioprine: additive bone‑marrow suppression; monitor blood counts closely. - Warfarin: may increase INR; monitor coagulation parameters.